Image of Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the
treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial

LITERATURE

Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial


Treatment with non-steroidal anti-inflammatory drugs (NSAID) is a common component of treatment regimens for rheumatoid arthritis (RA). Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the treatment of RA at a dose of 90 mg. The current study further evaluated the efficacy of etoricoxib 60 mg and 90 mg in RA patients with active disease


Availability

Orinox-004Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
BMC Musculoskeletal Disorders (2016) 17:331
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous